Hydrocortisone tablets (Actavis UK and Concordia)
Hydrocortisone tablets (Actavis UK and Concordia)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Hydrocortisone tablets (Actavis UK and Concordia)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline, commentary and related cases.

Case facts

Outline CMA Article 101 TFEU/Chapter I investigation into Actavis UK and Concordia in relation to alleged illegal agreements incentivising delayed entry into the market for hydrocortisone tablets.

Latest developments The CMA issued a statement of objections on 3 March 2017 to Actavis UK and Concordia.

Parties Actavis UK is a pharmaceutical company, ultimately owned by Allergan plc, a US-based global pharmaceutical group. During the time of the alleged wrong-doing, Actavis UK included:
• Auden Mckenzie (Pharma Division) Limited
• Auden Mckenzie Holdings Limited
• Actavis UK Limited (from 29 May 2015 until 24 June 2016)
• Allergan plc (from 29 May 2015 until 24 June 2016).

Concordia is a US-headquartered pharmaceutical group. During the time of the alleged wrong-doing, Concordia included:
• Amdipharm Limited
• Concordia International Rx (UK) Limited (Concordia Rx) (formerly known as Amdipharm Mercury Company Limited)
• Concordia International (Jersey) Limited (formerly known as Am